US FDA Approves 30-Minute Onset Of Action For Focalin(R) XR, Bringing Potential Benefits To ADHD Patients During Early Morning Period
Nov 21st 2008Drug InformationADHD
The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for Focalin(R) XR (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), bringing potential benefits for young patients and their families during the important morning period when they are preparing for school.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
